China's Dongcheng Biochemicals to Team With Japan's Nihon on Radioactive Drugs
Tang Shihua
DATE:  Jan 21 2019
/ SOURCE:  yicai
China's Dongcheng Biochemicals to Team With Japan's Nihon on Radioactive Drugs China's Dongcheng Biochemicals to Team With Japan's Nihon on Radioactive Drugs

(Yicai Global) Jan. 21 -- Dongcheng  Biochemicals plans to join hands with Japan's Nihon Medi-Physics to  develop radioactive imaging technologies and medicine. 

Dongcheng penned an agreement regarding  an initial cooperation intention with Nihon, the Shandong province-based  firm said in a statement on Jan. 18. 

The pair will research and develop  single-photon emission and positron emission tomography, as well as  nuclear medicine. The Chinese firm said that there is still some  uncertainly in terms of materializing the deal into a contract.

Upon completion, the partnership would  expand Dongcheng's product portfolio, industry chains, and foster new  profit growth, according to the statement. Nuclear medicine is the focus  of the firm's business development strategy for the next 10 years,  according to its website.

Tokyo's Nihon, a joint venture between  Sumitomo Chemical and Chicago-based GE Healthcare, occupies about 70  percent of the Japanese radioactive medicine market. 

Editor: Emmi Laine 

Follow Yicai Global on
Keywords:   Radio Active Medicine,Nihon Medi-Physics,Japan,Dongcheng Biochemicals